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Open access under CC BYParticulate matter (PM) collected from mainstream tobacco smoke is a test article commonly used for
in vitro genotoxicity and cytotoxicity testing of combustible tobacco products. However, little published
data exists concerning the stability of PM. We completed a 2 year study to quantify the effect of PM stor-
age at 80 C, on the genotoxicity and cytotoxicity of PM generated from 3R4F and M4A reference ciga-
rettes. The Ames test, Micronucleus assay (MNvit), Mouse Lymphoma assay (MLA) and the Neutral Red
Uptake assay (NRU) were used. The majority of M4A and 3R4F PMs were genotoxic and cytotoxic at
the timepoints tested. Some minor but statistically signiﬁcant differences were observed for stored ver-
sus freshly prepared PM, but the magnitude of changes were within the variability observed for repeat
testing.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Tobacco smoke is a complex and dynamic aerosol that consists
of a particulate matter (PM) phase and a gas-vapour phase (GVP)
(Scian et al., 2009). Routine toxicological assessment of tobacco
smoke commonly uses the PM fraction of the smoke aerosol. PM
is easily collected from mainstream tobacco smoke by a variety
of methods (Wan et al., 2009) and produces consistent and repro-
ducible responses in vitro. In addition there is a history of use of PM
in a variety of in vitro assays including the Neutral Red Uptake as-
say (NRU), the in vitro micronucleus (MNvit) and the Ames test
extending over 30 years and more recently, the Mouse LymphomaT, British American Tobacco;
eration Centre for Scientiﬁc
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-NC-ND license.assay (MLA) (Bakland et al., 2005; CORESTA, 2004; Wan et al.,
2009).
Several guidelines such as those developed by the International
Conference on Harmonisation (ICH, 2011) and Committee on
Mutagenicity (COM, 2011) suggest using a battery of core in vitro
assays for the detection of mutagenicity and potential for carcino-
genicity. In the case of tobacco products, Health Canada require the
Ames test, the MNvit and NRU data (Health Canada, 2005). In the
absence of speciﬁc regulatory guidelines, the CORESTA in vitro Tox-
icology Taskforce (CORESTA, 2004) recommend (i) a bacterial
mutagenicity assay (Ames Salmonella mutagenicity assay); (ii) a
mammalian cell assay for cytogenetics/mutation (MNvit, chromo-
some aberration assay or the MLA); and (iii) a cytotoxicity assay
(NRU).
The OECD principles of GLP and compliance monitoring (OECD,
1998) section 6 speciﬁes that the Sponsor must detail the expiry
date, speciﬁc storage instructions and stability of the test article.
For PM, limited information is available regarding these criteria,
with the exception of a 1 month expiry date for PM when stored
at 75 C and tested in the Ames test (Roemer et al., 2002). The
CORESTA in vitro Toxicology Task Force (CORESTA, 2004) recom-
mend: (i) PM extracts should be stored at 70 C within one hour
of extraction; (ii) extracts can be stored at 70 C for up to 4 years;
(iii) extracts should not be refrozen once thawed. The scientiﬁc
rationale to support these recommendations, however, has not
been published.
Table 1
Speciﬁcation of 3R4F and M4A reference cigarettes.
3R4F M4A
Tobacco blend USB* tobacco Flue-cured tobacco
Filter type Cellulose acetate Cellulose acetate
PM (mg/cig) 11.0 13.6
Tar (mg/cig) 9.4 11.3
Nicotine (mg/cig) 0.73 0.95
* United States blended.
Table 2
Results from Analysis of Covariance for stored and fresh 3R4F and M4A PMs.
Assay Treatment
condition
Concentration Analysis of Covariance
Stored v Fresh
M4A
Stored v Fresh
3R4F
Ames TA98 + S9 100 lg/plate NS NS
200 lg/plate NS NS
300 lg/plate * NS
TA100 + S9 100 lg/plate NS NS
200 lg/plate NS NS
300 lg/plate NS NS
TA1537 + S9 100 lg/plate NS NS
200 lg/plate NS NS
300 lg/plate NS NS
MLA 24 h-S9 20 lg/mL NS NS
25 lg/mL NS NS
30 lg/mL  *
MNvit 24 h-S9 30 lg/mL NS 
35 lg/mL  NS
NS, not signiﬁcant; , not analysed.
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sioned a study on PM prepared from two reference cigarettes, 3R4F
and M4A (Table 1). The PMs were stored at 80 C for approxi-
mately 2 years and tested at deﬁned intervals in the Ames test,
MNvit, MLA and NRU assay. Freshly prepared PM was generated
and tested simultaneously for comparison. The outcome of this
study provides scientiﬁc data to support a recommendation for
the maximum storage time of PM at 80 C, i.e. an expiry date.* p 6 0.052. Materials and methods
2.1. Cigarettes
Two reference cigarettes were evaluated in this study. M4A, a
100% ﬂue cured tobacco product (British American Tobacco’s his-
torical control) and 3R4F, a ‘US style’ blended product (University
of Kentucky). Cigarette parameters are detailed in Table 1.
2.2. Particulate matter preparation
All PMs were generated (according to ISO pufﬁng parameters;
35 mL puff volume, taken over 2 s, every 60 s) and extracted in
DMSO at British American Tobacco, Southampton, as previously
described in McAdam et al., 2011. All extracts were frozen at
80 C and transported to Covance Laboratories Ltd. UK on dry
ice where upon receipt they were stored at 80 C. The choice of
storage temperature was dictated by the transportation of PMs
on dry ice (78.5 C) and the need to avoid further ﬂuctuations
in storage temperature.
For the determination of storage effects, sufﬁcient PM from
3R4F and M4A cigarettes were prepared at the beginning of the
study to provide sufﬁcient test article for the 2 year period. PMs
were divided into 1 mL aliquots to avoid freeze–thawing. Fresh
3R4F and M4A PMs were prepared at 1 (T1), 3 (T3), 6 (T6), 12
(T12), 18 (T18) and 24 (T24) months, transported to Covance Labora-
tories Ltd. UK and stored as above. At each timepoint, ‘fresh’ PMs
were subsequently tested within 10 days with the respective
‘stored’ PM.
2.3. In vitro toxicology testing
All in vitro toxicology testing was conducted at Covance Labora-
tories Ltd. UK. Appropriate positive and negative controls were
used in each assay. Treatment conditions were selected based on
responsiveness to tobacco products as described in Combes et al.,
2012. Where speciﬁed, the mammalian liver post-mitochondrial
fraction (S9) (Mol Tox™) was used for metabolic activation.
2.4. Ames test
The Ames test was performed according to the principles of
OECD Test Guideline 471 (OECD, 1997a). Pre-incubation was used
with tester strains TA98, TA100 and TA1537, in the presence of 10%
S9 mix, with three replicates per concentration.2.5. MLA
The MLA used L5178Y cells, using a Microtitre ﬂuctuation
technique, according to the principles of OECD Test Guideline
476 (OECD, 1997b). Two replicates per concentration were assayed
for 24 h.2.6. MNvit
For the MNvit, PMs were tested according to the principles of
OECD Test Guideline 487 (OECD, 2010) in V79 cells for 24 h, four
replicates per concentration.2.7. NRU
For the NRU assay, PMs were tested in Balb/c 3T3 cells, six rep-
licates per concentration, based on guidance described in ICCVAM
‘‘in vitro cytotoxicity methods for estimating starting doses for
acute oral systemic toxicity testing’’ (ICCVAM, 1996). The PM con-
centration resulting in 50% toxicity in the NRU test (IC50) were de-
rived by Phototox Version 2 (OECD, 2004).2.8. Statistics
2.8.1. Ames, MLA, MNvit
For each stored and fresh PM (M4A and 3R4F), assay, treatment
condition and common concentration (on the linear part of the
dose response curve), separate regression lines were ﬁtted across
time (T0, T1, T3, T6, T12, T18 and T24 months) to test whether there
was a signiﬁcant response across time (i.e. a signiﬁcant slope).
An analysis of covariance (ANCOVA) model was then applied to
test whether the response with each stored PM compared to that
with each fresh PM, by time interaction was signiﬁcant (i.e. signif-
icantly non-parallel slopes). Data analysis were performed with
SAS, Version 9.2 (SAS Institute Inc.: Cary, North Carolina, USA
2002–2008).
The resolving power of the assays used in this study have been
evaluated to have a resolving power of 80% to detect a 30% differ-
ence with 3 and 4 replicates in the Ames test and MNvit, respec-
tively, and between 18 to 85% difference in the MLA with 2
replicates. The NRU is able to detect 18–49% difference between
PMs (Oldham et al., 2012).
Fig. 1. Comparison of stored and fresh PMs when data from the 2 year period is combined for the induced revertants in the Ames test. (A) M4A TA98 + S9; (B) M4A TA100 + S9
(T18 stored data removed from analysis); (C) M4A TA1537 + S9 (T18 stored data removed from analysis); (D) 3R4F TA98 + S9; (E) 3R4F TA100 + S9 (T18 stored and fresh data
removed from analysis); (F) 3R4F TA1537 + S9; h 100 lg/plate; 200 lg/plate; 300 lg/plate.
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3.1. Ames test, MLA and MNvit
In all instances, PM concentrations were selected to provide
data points on the linear portion of the dose response curve. The
majority of PMs induced statistically signiﬁcant (P 6 0.05) concen-
tration dependent genotoxic responses in the Ames test, MLA and
MNvit. However, at T18 stored 3R4F and M4A, plus fresh 3R4F PM
in Ames strain TA100 did not induce mutation. Stored M4A in
TA1537 at T18 also did not induce mutation. All non-inducing
PMs were removed from analysis. At T1, stored 3R4F in the MLAat 30 lg/mL was also removed from analysis due to excessive het-
erogeneity between replicates, as determined by an F-test.
Stored 3R4F and M4A PMs were compared to their respective
freshly prepared PMs using ANCOVA (Table 2). Some statistically
signiﬁcant differences (P 6 0.05) were observed between stored
and fresh M4A PMs in the Ames tester strain TA98 at 300 lg/plate
(Table 2). However, the linear regression analysis showed that the
source of the difference was from fresh and not stored PM. Similar
statistical differences were observed between stored and fresh
3R4F PMs in the MLA at 30 lg/mL (Table 2). However, the observed
differences are not consistent across all the doses analysed or both
PMs (Table 2). For all other concentrations analysed, there were no
Fig. 2. Comparison of stored and fresh PMs when data is combined for the induced
mutation frequency in the MLA using L5178Y cells. (A) M4A; (B) 3R4F;h 20 lg/mL;
25 lg/mL; 30 lg/mL. Stored M4A at T1 was removed from analysis due to
excessive heterogeneity between replicate cultures.
Fig. 3. Comparison of stored and fresh PMs when data is combined for the induced
micronucleated binucleates in the MNvit using V79 cells. (A) M4A at 30 lg/mL; (B)
3R4F at 35 lg/mL.
Fig. 4. NRU using Balb/c cells, comparison of stored and fresh PMs when IC50 values
are combined.
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In addition, the data were combined for each storage condition,
for each PM and each concentration analysed, in each assay over
the 2 year period (Figs. 1–3). The ﬁgures demonstrate that the
combined induced responses at the concentrations analysed were
comparable between the stored and fresh samples. Therefore, dif-
ferences in assay responses did not show any consistency or pat-
tern that was indicative of a true time-related effect, and as such
the sporadic differences were attributed to biological assay
variability.
3.2. In vitro cytotoxicity assay
For each timepoint and PM, a concentration related decrease in
cell viability was observed in the NRU, which allowed IC50 values to
be calculated. A lower IC50 value indicates higher cytotoxicity. The
IC50 values for fresh and stored 3R4F PMs differed at each individ-
ual timepoint. However, there was no trend with time over the
duration of the study. The same observation was made for fresh
and stored M4A PMs. The differences observed were within the
ranges of repeat testing of PMs (Fig. 4).
The combined data for all timepoints (Fig. 4) indicate that there
is no difference over time between fresh and stored samples with
the variance overlapping for each PM.4. Conclusion
The objective of this study was to determine whether storing
3R4F and M4A PMs at 80 C for 2 years affected the responses
of the Ames test, MNvit, MLA and NRU assays. Stored and freshPMs were tested in the in vitro assays at 7 timepoints over the
2 year period. We found that, when fresh and stored 3R4F and
M4A PMs were compared on a dose-for-dose basis, the majority
of concentrations analysed were not signiﬁcantly different. Where
differences were observed, they showed no consistent trends or
patterns and therefore these differences were considered to be
chance events that were due to normal biological variability within
the assay combined with the multiplicity of testing.
It is concluded that, within the sensitivity and speciﬁcity of the
assay systems used, PM can be stored for up to 2 years at 80 C
without affecting its ability to induce genotoxicity or cytotoxicity.
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